1. Home
  2. HSDT vs GLSI Comparison

HSDT vs GLSI Comparison

Compare HSDT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HSDT

Helius Medical Technologies Inc. (DE)

HOLD

Current Price

$2.70

Market Cap

123.1M

Sector

Health Care

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$21.68

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSDT
GLSI
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.1M
123.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HSDT
GLSI
Price
$2.70
$21.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$39.00
AVG Volume (30 Days)
551.8K
641.8K
Earning Date
11-18-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$75.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
87.45
N/A
52 Week Low
$2.67
$7.78
52 Week High
$1,200.00
$30.82

Technical Indicators

Market Signals
Indicator
HSDT
GLSI
Relative Strength Index (RSI) 29.93 78.23
Support Level $2.67 $13.11
Resistance Level $2.86 $30.82
Average True Range (ATR) 0.30 3.19
MACD 0.08 1.33
Stochastic Oscillator 3.07 57.82

Price Performance

Historical Comparison
HSDT
GLSI

About HSDT Helius Medical Technologies Inc. (DE)

Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: